LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER| Amgen
Amgen's LUMAKRAS (sotorasib) approved in Japan for KRAS G12C-mutated advanced non-small cell lung cancer. Approval based on Phase 2 trial results showing 37% objective response rate. Amgen's drug is now approved in nearly 40 countries.
How this was made
The 30-second read
Why it matters
The approval expands Amgen's addressable market and could lift earnings forecasts.
Market read
Regulatory clearance in Japan is a material catalyst for Amgen, likely prompting a positive stock reaction.
What to watch
Potential reimbursement challenges in Japan and competition from upcoming KRAS inhibitors.
Background
Amgen announced the first Japan approval for its KRAS G12C inhibitor LUMAKRAS, following approvals in ~40 countries.
Ticker impact
Amgen received Japanese regulatory approval for LUMAKRAS (sotorasib) to treat KRAS G12C‑mutated NSCLC, a first‑in‑Japan approval expanding its market.
upside as investors price in additional sales potential in Japan
Regulatory clearance in a major market adds a new revenue stream; peers lack a Japan‑approved KRAS G12C drug.
Market effects
Strengthens the oncology/targeted‑therapy sector as a benchmark KRAS G12C approval.
Adds to Japan's oncology pipeline, may spur competitive responses.
Highlights Amgen's leadership in KRAS‑targeted drugs worldwide.
Counterpoint
If Japanese uptake is slow or pricing is constrained, the stock may not see a sustained rally.
Key entities
- CompanyAmgen
Developer of LUMAKRAS, a KRAS G12C inhibitor.
- RegulatorJapan Ministry of Health, Labour and Welfare
Granted approval for LUMAKRAS in Japan.
